Agree one million percent! In the midst of all the endorsements coming from all different corners of the world, the generics and DS industries and BPs will have no complaints when the panel and subsequently FDA approves the broadest label, imo. Those even buying the highest strike of call options from January and beyond will still make a ton of money, imo.